Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

Item

http://www.wikidata.org/entity/Q28195423

Q28195423

about

The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)The effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)Aspirin and clopidogrel resistance: consideration and management Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.Antiplatelet drugs in cardiological practice: established strategies and new developments Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome.Platelet interactions as therapeutic targets for prevention of atherothrombosis.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Cangrelor: a novel P2Y12 receptor antagonist.P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Platelet P2Y12 receptor inhibition by thienopyridines: status and future.Cangrelor: a review on its mechanism of action and clinical development.Personalized antiplatelet therapy for coronary artery disease patients: is this the future?Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.Update on the clinical development of cangrelor.Antiplatelet therapy in acute coronary syndromes.Review: Antiplatelet drugs: what comes next?Antiplatelet therapy and vascular disease: an update.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.Management of antiplatelet therapy inpatients at risk for coronary StentThrombosis undergoing non-cardiac surgery.Emerging antiplatelet agents, differential pharmacology, and clinical utility.Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.Modern antiplatelet agents in coronary artery disease.Pharmacotherapy for the reduction of stent thrombosis.Emerging antithrombotic drugs for acute coronary syndrome.Cangrelor: a review on pharmacology and clinical trial development.Cangrelor for treatment of arterial thrombosis.Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention.Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).Use of novel antiplatelet agents in acute coronary syndromes.The progress in the research of antiplatelet agents (1995-2017).A Safety Evaluation of Cangrelor in Patients Undergoing PCI.

P2860

Q24187718-D8375B85-F80F-4718-BC09-A70D02AC7D8F Q24197708-6A3EDFAA-DFDF-4363-B895-52988716C36A Q28200610-DE50DCE2-BCD3-48F2-ACCF-45BD5F2D7857 Q33685876-7E193771-1D4B-49EC-9ADE-A030E43CD972 Q33902628-BDB91D7E-EA16-4FB4-9F15-D87474FE36A2 Q34771381-426E5109-8812-428B-BFE8-2D29CAB347F5 Q34994015-97F0168C-0A16-49A3-B84F-8768D0EACE33 Q35569714-0CE7499D-E4DF-4323-A03E-56E3F70127BA Q35752611-B96F86FE-C98B-4C58-A2C0-40D3A280D758 Q36787291-1E7E3961-2699-4E7E-A6B9-E20AA6527D80 Q36835862-48E98C5B-23AC-463D-AD92-8D4A335514A8 Q37311337-2E260B25-D9E5-4691-B709-C56C0CC7B3ED Q37486621-2D6B81FD-3670-4626-885B-8447AEAB7330 Q37550156-2DC605FF-2F0C-4BCA-8550-134BC77F7D56 Q37551923-4CA5B044-0655-4A1C-9E0F-32CE5C2F625B Q37562606-6B43E9EB-8F77-410E-9256-26F03E860307 Q37579228-78B435DD-F801-477E-B258-2D7A89CD64C8 Q37611039-E6EB73F9-5541-43BD-A140-C3F3EC90ADC1 Q37642822-585472B9-D829-4644-9D72-867AF6C20946 Q37714189-0D9E5C39-6462-4A88-A574-9156E9B30E76 Q37752222-9F9C0E08-C44D-4B49-B173-EB801A31C331 Q37776511-F88B7BAD-C28F-4F6D-87F6-7CD1117EEBFA Q37798110-B8AECCAF-CF1C-48CA-B1D0-32CD6195038A Q37809630-D98E3743-39FC-4F89-BB7C-036EA008DCD1 Q37838100-3CD020E5-FBD8-418F-9E98-F485D0FEA7C0 Q37923969-4FCECA9C-19CE-4DB8-AEDE-D35D4C76301B Q37925007-67E0B633-6604-44D4-92C7-BEC035391896 Q37937717-7C8080C6-622E-479B-BFF7-DF294DB493D5 Q37979178-179B9055-2EE3-46BF-A5F9-0736C6D06263 Q38037672-5B54CC61-4E50-41E1-A737-088F57D18C85 Q38063289-AA153F6F-AD0B-4D23-BE19-88A9BAB4490B Q38101963-60ADCFBF-057D-4145-AB61-449F841A998F Q38121144-CF5EE010-943D-4CB4-B593-E2FCED072ECF Q38153779-0814EC3C-CF06-49EB-82E0-B28C5FF41C41 Q38183489-6A638438-EC42-464C-8BBC-804987125AA5 Q38197732-F686CB09-CB86-4994-A826-466E634457BD Q38216215-C1CEAA1A-58BA-420B-9AE8-14C0980BDD83 Q38348649-EE4CF0A6-0FD3-4775-BDD6-7EA1A2F98EF6 Q38669003-AD9732E8-351D-4B5E-9778-38F79FD11994 Q38672923-6BCF7AE6-9F80-4C6F-8D62-D0BC6702FF34

P2860

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

Item

http://www.wikidata.org/entity/Q28195423

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu